替吉奥联合阿帕替尼治疗晚期胃癌的效果观察  

Effect of tegio combined with apatinib in the treatment of advanced gastric cancer

作　　者：刘晓钰[1] Liu Xiaoyu(Department of Oncology,Dezhou People’s Hospital,Dezhou 253000,China)

机构地区：[1]山东省德州市人民医院肿瘤内科,253000

出　　处：《中国实用医刊》2020年第14期104-106,共3页Chinese Journal of Practical Medicine

摘　　要：目的:探讨替吉奥联合阿帕替尼治疗晚期胃癌的临床效果。方法:抽取2018年1月至2019年1月德州市人民医院收治的晚期胃癌患者90例,根据盲抽法将其分为两组,每组45例。对照组口服替吉奥,在此基础上,观察组加服阿帕替尼。两个疗程后,比较两组患者临床疗效、糖类抗原199(CA199)、糖类抗原242(CA242)、癌胚抗原(CEA)水平及不良反应发生情况。结果:两个疗程后,观察组总缓解率为88.89%,高于对照组(71.11%),CA199、CA242及CEA水平低于对照组,差异有统计学意义(P<0.05);治疗期间,观察组不良反应总发生率(28.89%)低于对照组(42.22%),差异未见统计学意义(P>0.05)。结论:替吉奥联合阿帕替尼治疗晚期胃癌患者,可有效降低肿瘤标志物水平,治疗效果明显,且安全性较高。Objective To explore the clinical effect of tegio combined with apatinib in the treatment of advanced gastric cancer.Methods Ninety patients with advanced gastric cancer admitted to Dezhou People’s Hospital from January 2018 to January 2019 were selected.According to the method of blind sampling,they were divided into two groups,with 45 cases in each group.The control group took tegio orally,on this basis,the observation group took apatinib.After two courses of treatment,the clinical efficacy,the levels of carbohydrate antigen 199(CA199),carbohydrate antigen 242(CA242),carcinoembryonic antigen(CEA)and adverse reactions were compared between the two groups.Results After two courses of treatment,the total remission rate of the observation group was 88.89%,which was higher than that of the control group(71.11%),and the levels of CA199,CA242 and CEA were lower than those of the control group(P<0.05);during the treatment,the total incidence of adverse reactions in the observation group(28.89%)was lower than that of the control group(42.22%),and the difference was not statistically significant(P>0.05).Conclusions Tegio combined with apatinib in the treatment of advanced gastric cancer patients can effectively reduce the level of tumor markers,the treatment effect is obvious,and the safety is high.

关 键 词：胃癌 晚期 替吉奥 阿帕替尼 肿瘤标志物 

分 类 号：R735.2[医药卫生—肿瘤]